Myriad Genetics (MYGN) Capital Expenditures (2009 - 2026)

Myriad Genetics has disclosed Capital Expenditures across 18 years of filings, most recently posting $5.4 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 1.89% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $15.7 million (down 10.8% YoY), while the FY2025 annual figure was $15.6 million, down 17.89% from the prior year.
• Capital Expenditures improved to $5.4 million in Q1 2026, from $4.7 million in the prior quarter.
• Over the last five years, Capital Expenditures for MYGN reached as high as $56.6 million in Q4 2023 and fell as low as -$35.7 million in Q3 2023.
• The 5-year median for Capital Expenditures is $5.3 million (2025), against an average of $8.7 million.
• The widest YoY moves for Capital Expenditures: up 1232.35% in 2022, down 533.33% in 2022.
• A 5-year view of Capital Expenditures shows it stood at $45.3 million in 2022, then rose by 24.94% to $56.6 million in 2023, then tumbled by 93.64% to $3.6 million in 2024, then soared by 30.56% to $4.7 million in 2025, then increased by 14.89% to $5.4 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $5.4 million, $4.7 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.